Belgium: Punching Well Above its Weight in Clinical Trials
Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to…
Address: Archimedesstraat 11 – B1000 Brussels,Belgium
Tel: +32 2 285 42 00
Web: http://www.apb.be/Content/Default.asp
The General Pharmaceutical Association (APB) is the umbrella federation of the Belgian associations of independent pharmacists. APB represents 90 percent of the pharmaceutical corps, which essentially covers the total of the corresponding independent pharmacists.
The activities of the APB includes the advocacy of its members as well as other forms of assistance and information to its members.
Under the control of the General Assembly shall determine the general policy of the Federal Council, which is followed by the Management Committee. This includes not only ‘contacts’ with the Federal Government, Regions, Communities and the official authorities, but also the representation in the lap of numerous committees both at regulatory level and in terms of the health of the drug delivery control.
The APB members provide services including legal assistance, social and economic information, scientific and pharmaceutical documentation, etc.
In addition, the Office for Drug Research (DGO) part of the APB. The core of this officially recognized and accredited laboratory analysis, monitoring and systematic, periodic rechecking of medicines and products with a quality label.
Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to…
Xavier De Cuyper introduces the Federal Agency for Medicines & Health Products (FAMHP) and the essential role it plays in Belgium’s healthcare regulatory framework since being founded in 2007. De…
Chantal Depondt, president of the Belgian Neurological Society (BNS), introduces the mission of the professional association and offers her insights into the healthcare and research dynamics surrounding neurological diseases. Depondt…
Javier Aracil, country manager of Allergan in Belgium and Luxembourg, introduces the priorities and objectives as he set as he entered his first country manager position coming from holding key…
Isabelle De Walsche, managing director of Gedeon Richter in Belgium, the Netherlands, and Luxembourg gives an update on the affiliate’s development since its establishment in 2012. De Waslche goes on…
Brecht Vanneste, associate VP and managing director of MSD in Belgium and Luxembourg, highlights the strategic significance of the affiliate as an important location for early-stage clinical trials and home…
Teun Grooters, co-founder and CEO of Arega – the exclusive distributor of Teva generics in Belgium – tells the story of the newly founded pharmaceutical company and shares his future…
Belgian Former Minister of Social Affairs, Public Health and Asylum & Migration Maggie de Block outlines some of the key reforms her Ministry has rolled out since she took office…
Frank Swaelens, general manager of IQVIA in Belgium and Luxembourg, offers insights into the healthcare and life science ecosystem of Belgium and highlights the opportunities that exist for the country…
Françoise Smets, dean of the Faculty of Medicine and Dentistry at Université Catholique de Louvain (UCLouvain), introduces the innovation and research capacity of the institution as the top-ranking French-speaking university…
Teva Pharma Belgium’s Eric Deschepper outlines how the global group’s restructuring has impacted its Belgian operations, its realignment from a pure generics to a specialty pharma player, and how the…
Over the past few decades, pharma multinationals have been increasingly drawn to the highly cost-competitive markets of Central Eastern Europe (CEE) and Asia to situate major manufacturing sites. However, despite…
See our Cookie Privacy Policy Here
